Table 1 Characteristics of enrolled patients
Characteristic | EGFR-mutated | Without EGFR amplification | With EGFR amplification | P value |
|---|---|---|---|---|
N(%) | N(%) | N(%) | ||
Age | 0.804 | |||
<70 | 88(74.21%) | 71 (74.74%) | 17 (77.27%) | |
≥70 | 29(24.79%) | 24 (25.26%) | 5 (22.73%) | |
Gender | 0.064 | |||
Female | 70(59.83%) | 53 (55.79%) | 17 (77.27%) | |
Male | 47(40.17%) | 42 (44.21%) | 5 (22.73%) | |
ECOG score | 0.944 | |||
0 | 22(18.81%) | 18 (18.95%) | 4 (18.18%) | |
1 | 71(60.68%) | 57 (60.00%) | 14 (63.64%) | |
2 | 24(20.51%) | 20 (21.05%) | 4 (18.18%) | |
Smoking | 0.167 | |||
No | 101(86.32%) | 80 (84.21%) | 21 (95.45%) | |
Yes | 16(13.68%) | 15 (15.79%) | 1 (4.55%) | |
Type of lung carcinoma | 0.35 | |||
Adenocarcinoma | 111(94.87%) | 91 (95.79%) | 20 (90.91%) | |
Others (non-squamous NSCLC) | 6(5.13%) | 4 (4.21%) | 2 (9.09%) | |
TNM stage | 0.604 | |||
IVA | 27(23.08%) | 21 (22.11%) | 6 (27.27%) | |
IVB | 90(76.92%) | 74 (77.89%) | 16 (72.73%) | |
Brain metastasis | 0.755 | |||
No | 62(52.99%) | 51 (53.68%) | 11 (50.00%) | |
Yes | 55(47.01%) | 44 (46.32%) | 11 (50.00%) | |
Bone metastasis | 0.865 | |||
No | 46(39.32%) | 37 (38.95%) | 9 (40.91%) | |
Yes | 71(60.68%) | 58 (61.05%) | 13 (59.09%) | |
Liver metastasis | 0.277 | |||
No | 104(88.89%) | 83 (87.37%) | 21 (95.45%) | |
Yes | 13(11.11%) | 12 (12.63%) | 1 (4.55%) | |
Lung metastasis | 0.778 | |||
No | 66(56.41%) | 53 (55.79%) | 13 (59.09%) | |
Yes | 51(43.59%) | 42 (44.21%) | 9 (40.91%) | |
Pleural metastasis | 0.764 | |||
No | 82(70.09%) | 66 (69.47%) | 16 (72.73%) | |
Yes | 35(19.91%) | 29 (30.53%) | 6 (27.27%) | |
EGFR mutation | 0.861 | |||
19del | 49(41.88%) | 39 (41.05%) | 10 (45.45%) | |
21-L858R | 60(51.28%) | 49 (51.58%) | 11 (50.00%) | |
other | 8(6.84%) | 7 (7.37%) | 1 (4.55%) | |
T790M (initial) | 0.944 | |||
No | 112(95.73%) | 91 (95.79%) | 21 (95.45%) | |
Yes | 5(4.27%) | 4 (4.21%) | 1 (4.55%) | |
TP53 mutation | 0.016 | |||
No | 42(35.90%) | 39 (41.05%) | 3 (13.64%) | |
Yes | 75(64.10%) | 56 (58.95%) | 19 (86.36%) | |
Radiotherapy | 0.402 | |||
No | 83(70.94%) | 69 (72.63%) | 14 (63.64%) | |
Yes | 34(29.06%) | 26 (27.37%) | 8 (36.36%) | |
Initial treatment | 0.548 | |||
1 generation TKI | 65(55.56%) | 55 (57.89%) | 10 (45.45%) | |
2 generation TKI | 14(11.97%) | 12 (12.63%) | 2 (9.09%) | |
3 generation TKI | 31(26.49%) | 23 (24.21%) | 8 (36.36%) | |
1 generation TKI + Anlotinib | 7(5.98%) | 5 (5.26%) | 2 (9.09%) |